A revolutionary precision laser treatment for all skin types
Independent company founded with our lead investor partner, Craig Drill Capital
Billions of people with skin of color have long had largely ineffective treatment options for their skin conditions. Long-lasting hyperpigmentation and melasma affect darker skin tones at a far higher rate, and safe skin rejuvenation remains a challenge for affected patients. AVAVA, Inc., is poised to offer them a revolutionary new treatment paradigm.
Next-gen 3D precision laser platform
First developed in our Innovation Studio, the transformative new 3D laser technology in development at AVAVA, Inc., finally delivers precision therapy safe for all skin types.
Safe and effective, with integrated visualization, this novel platform enables smart selective treatments and advanced machine learning capability for treatment optimization. The versatile and extendable platform enables the treatment of multiple clinical indications, including a treatment of hyperpigmentation and melasma in skin of color — a market expected to reach $7.23B by 2026.
Melasma/Post-inflammatory hyperpigmentation (PIH)
Rejuvenating skin of color:
A breakthrough in spatially selective laser treatment, the AVAVA platform is designed to focus therapeutic energy directly on hyperpigmentation below the epidermis. The laser’s unique optics reducing surface fluence and intensity, reducing damage to surrounding tissues, eliminating the need for surface-level contrast, and making the laser highly effective for patients with darker skin.
World-renowned management
The AVAVA commercial launch team is helmed by an unrivalled team of experts in photomedicine, dermatology, and the global business of energy-based therapeutics.
